We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 15, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. (ABBV - Free Report) , Intel Corp. (INTC - Free Report) , The Boeing Co. (BA - Free Report) and Tandy Leather Factory, Inc. (TLF - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for AbbVie, Intel and Boeing
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Intel Corp. and The Boeing Co., as well as a micro-cap stock Tandy Leather Factory, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
AbbVie's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+32.1% vs. +25.7%). The company has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications.
AbbVie's oncology and neuroscience drugs are also contributing to top-line growth. AbbVie is returning to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE. The company has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline.
However, the company faces several headwinds like Humira LOE impact, increasing competitive pressure on Imbruvica and continued macro headwinds for Aesthetics. Estimates are stable ahead of Q4 earnings. AbbVie has a positive record of earnings surprises in recent quarters.
Shares of Intel have outperformed the Zacks Semiconductor - General industry over the past six months (+108.8% vs. +8.9%). The company is gaining solid traction in the AI infrastructure market. It has recently introduced Intel Core Ultra Series 3 processors (codenamed Panther Lake), which is designed to power a broad spectrum of consumer and commercial AI PCs, gaming devices and edge solutions.
The acquisition of Mobileye has helped the company to rapidly penetrate the autonomous car technology market, currently dominated by the likes of NVIDIA and Qualcomm. Significant capital infusion has helped it to further focus on chip innovation. Focusing on cost optimization is a positive.
However, Intel is witnessing intensifying competition in the server, storage and networking markets. Delay in 7 nm process-based chips, which is renamed as Intel 4, is a major concern. High debt levels might limit sufficient cash flow generation and impact investors' confidence.
Boeing's shares have outperformed the Zacks Aerospace - Defense industry over the past year (+45.9% vs. +37.8%). The company remains one of the largest commercial aircraft manufacturers in the world. Steadily growing commercial air travel should boost Boeing's service business unit. The outlook for Boeing's defense and space business segment also remains optimistic. The Zacks analyst model expects the company's total revenues to increase during 2025-2027.
However, Boeing faces risks related to shortage of skilled labor. Trade tensions between the United States and China may cause Boeing to be unsuccessful in the timely delivery of its 737 jets and thereby hurt its operational performance. Supply-chain issues and heightened U.S. import tariffs also pose a threat to this stock.
Shares of Tandy Leather Factory have underperformed the Zacks Retail - Apparel and Shoes industry over the past year (-6.9% vs. +2.4%). This microcap company with a market capitalization of $22.43 million has posted a $24.9 million HQ sale, delivered a $16.2 million pre-tax gain, is boosting YTD net income to $10 million from $0.5 million YoY and enabling a strategic shift to an asset-light model.
Liquidity is strong, with $12 million in cash and full availability on a $5 million credit facility. Gross margin rose to 58.2% (vs. 57.4%), reflecting pricing strength. The company is expanding digital and commercial channels alongside a high-touch retail presence across 101 stores, enhancing brand loyalty and diversification.
However, concerns persist: flat sales ($54.1 million), a $0.4 million operating loss, and a $5.5 negative cash flow despite headline earnings. Rising tariffs pose risks to gross margin. Management's inaction on its buyback plan raises questions about capital deployment confidence. Shares are down 37% in the past year and trade at a steep discount (0.42X P/B vs. 7.04X industry).
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory
For Immediate Release
Chicago, IL – January 15, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. (ABBV - Free Report) , Intel Corp. (INTC - Free Report) , The Boeing Co. (BA - Free Report) and Tandy Leather Factory, Inc. (TLF - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for AbbVie, Intel and Boeing
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Intel Corp. and The Boeing Co., as well as a micro-cap stock Tandy Leather Factory, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> PPI Inflation Increases, Q4 Bank Earnings Higher
Today's Featured Research Reports
AbbVie's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+32.1% vs. +25.7%). The company has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications.
AbbVie's oncology and neuroscience drugs are also contributing to top-line growth. AbbVie is returning to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE. The company has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline.
However, the company faces several headwinds like Humira LOE impact, increasing competitive pressure on Imbruvica and continued macro headwinds for Aesthetics. Estimates are stable ahead of Q4 earnings. AbbVie has a positive record of earnings surprises in recent quarters.
(You can read the full research report on AbbVie here >>>)
Shares of Intel have outperformed the Zacks Semiconductor - General industry over the past six months (+108.8% vs. +8.9%). The company is gaining solid traction in the AI infrastructure market. It has recently introduced Intel Core Ultra Series 3 processors (codenamed Panther Lake), which is designed to power a broad spectrum of consumer and commercial AI PCs, gaming devices and edge solutions.
The acquisition of Mobileye has helped the company to rapidly penetrate the autonomous car technology market, currently dominated by the likes of NVIDIA and Qualcomm. Significant capital infusion has helped it to further focus on chip innovation. Focusing on cost optimization is a positive.
However, Intel is witnessing intensifying competition in the server, storage and networking markets. Delay in 7 nm process-based chips, which is renamed as Intel 4, is a major concern. High debt levels might limit sufficient cash flow generation and impact investors' confidence.
(You can read the full research report on Intel here >>>)
Boeing's shares have outperformed the Zacks Aerospace - Defense industry over the past year (+45.9% vs. +37.8%). The company remains one of the largest commercial aircraft manufacturers in the world. Steadily growing commercial air travel should boost Boeing's service business unit. The outlook for Boeing's defense and space business segment also remains optimistic. The Zacks analyst model expects the company's total revenues to increase during 2025-2027.
However, Boeing faces risks related to shortage of skilled labor. Trade tensions between the United States and China may cause Boeing to be unsuccessful in the timely delivery of its 737 jets and thereby hurt its operational performance. Supply-chain issues and heightened U.S. import tariffs also pose a threat to this stock.
(You can read the full research report on Boeing here >>>)
Shares of Tandy Leather Factory have underperformed the Zacks Retail - Apparel and Shoes industry over the past year (-6.9% vs. +2.4%). This microcap company with a market capitalization of $22.43 million has posted a $24.9 million HQ sale, delivered a $16.2 million pre-tax gain, is boosting YTD net income to $10 million from $0.5 million YoY and enabling a strategic shift to an asset-light model.
Liquidity is strong, with $12 million in cash and full availability on a $5 million credit facility. Gross margin rose to 58.2% (vs. 57.4%), reflecting pricing strength. The company is expanding digital and commercial channels alongside a high-touch retail presence across 101 stores, enhancing brand loyalty and diversification.
However, concerns persist: flat sales ($54.1 million), a $0.4 million operating loss, and a $5.5 negative cash flow despite headline earnings. Rising tariffs pose risks to gross margin. Management's inaction on its buyback plan raises questions about capital deployment confidence. Shares are down 37% in the past year and trade at a steep discount (0.42X P/B vs. 7.04X industry).
(You can read the full research report on Tandy Leather Factory here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.